NICE re-evaluation of oncology drugs

ISPOR 2018 NICE re-valuation of oncology drugs


Is NICE being nice in their re-evaluation of oncology drugs in the cancer drugs fund in England?

Since July 2016, NICE took over responsibility for the Cancer Drugs Fund (CDF) in England, which contained 25 drugs for 33 indications. Prior to 2016, the CDF in England provided funding for previously rejected oncology treatments and for those not yet assessed.

NICE is currently evaluating all existing treatments in the CDF to assess if they should be recommended for routine use by NHS England; retained in the CDF to gather additional evidence or not recommended.

This study investigates NICE’s evaluation of existing CDF treatments and its potential impact on funding and patient access.

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.